Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
ARD-101
product3 mentionslast seen Oct 23, 2026
Clinical-stage candidate for Prader-Willi Syndrome and metabolic diseases.
Relationships 9
- Aardvark Therapeutics, Inc.developsARD-10199% confidence3 sources
- ARD-101applies toPrader-Willi Syndrome treatment99% confidence2 sources
- ARD-101applies tometabolic diseases98% confidence2 sources
- ARD-101applies toPrader-Willi syndrome hyperphagia treatment95% confidence1 source
- U.S. Food and Drug AdministrationapprovesARD-10192% confidence1 source
- U.S. Food and Drug AdministrationapprovesARD-10190% confidence1 source
- ARD-101depends onbitter taste receptor activation88% confidence1 source
- ARD-101composed ofbitter taste receptor activation85% confidence1 source
- ARD-101applies tometabolic disease treatment85% confidence1 source
Relationship
Aardvark Therapeutics, Inc.developsARD-101
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGAROct 23, 2026Aardvark Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Aardvark Therapeutics, Inc. developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome and metabolic diseases, today reported exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective (HERO) trial
- filingSEC EDGAROct 22, 2026Aardvark Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
ARD-101 is being developed as a treatment for hyperphagia associated with Prader-Willi Syndrome
- filingSEC EDGAROct 8, 2026Aardvark Therapeutics, Inc. 8-K: Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS)